Oncimmune (LON:ONC) Issues Earnings Results

Oncimmune (LON:ONC) announced its quarterly earnings results on Monday. The company reported GBX (4.72) (($0.06)) EPS for the quarter, Digital Look Earnings reports. Oncimmune had a negative return on equity of 760.96% and a net margin of 586.08%.

Oncimmune Trading Up 5.1 %

ONC opened at GBX 8.01 ($0.10) on Wednesday. Oncimmune has a 1-year low of GBX 7.50 ($0.09) and a 1-year high of GBX 31 ($0.39). The firm has a 50-day moving average price of GBX 13.37 and a two-hundred day moving average price of GBX 14.80. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 806.85. The stock has a market capitalization of £5.94 million, a PE ratio of -267.13 and a beta of 1.19.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.